One study of patients with stage I-IV CRC found that KRAS mutated/MMR-D CRC had the shortest OS while KRAS WT/MMR-D CRC had the longest OS.19 Specifically, in early-stage MMR-D CRC, KRAS status has not been established to have prognostic value; this may be due to the smaller sample sizes and difficulty with reaching statistical significance.20,21 Our study evaluating over 1000 mCRC patients failed to identify this association; conversely, we discovered an association between wild-type RAS status and adverse survival outcome, although this did not persist on multivariate analysis. The gene discussed is KRAS; the disease is colorectal carcinoma.